FDA Orange Book · active-ingredient family
Retapamulin
Retapamulin: 1 brand, 0 generics; first approved Apr 12, 2007; on patent until Feb 14, 2027.
On patentHas discontinued products
Generic status & protection
Protected until Feb 14, 2027 (earliest listed patent expiry).
Earliest patent expiry
Brands (NDA)
1
Generics (ANDA)
0
Listed patents
1
Next patent expiry
Feb 14, 2027
in 4 mo
Brand (NDA) products
Originator applications
- ALTABAXRLDALMIRALLNDA 0220552007
Approved strengths under this FDA application. Strength Dosage form Route Status TE 1% OINTMENT TOPICAL Discontinued -
Patent & exclusivity timeline
Protection horizon
Patent expiryExclusivity endToday
Listed patents
Orange Book patent file
| Patent | Expires | In | Type |
|---|---|---|---|
| 7875630 | in 4 mo | Substance |
Approval history
FDA approval span
First approval
19 yr 10 mo ago
Most recent approval
19 yr 10 mo ago
All 1 application were approved in 2007.
Brand (NDA) 1100%
Generic (ANDA) 00%
Retapamulin: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Assyro Intelligence
Ask anything about Retapamulin
Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.
Evaluating for a team? Book a demo